Cited by 309Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy

Grundy, Scott M.·2002·Circulation

DOI 10.1161/01.cir.0000038419.53000.d6

Open this paper in CoChat — free account

Abstract

lthough low-density lipoprotein (LDL) is widely recognized as the major atherogenic lipoprotein and the primary target of lipid-lowering therapy, 1 other lipoprotein species nonetheless appear to be involved in atherogenesis.These include very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and highdensity lipoproteins (HDL).Both VLDL and IDL are triglyceride-rich lipoproteins (TGRLP).Thus, in the aftermath of unequivocal evidence that LDL lowering reduces risk for major coronary events and stroke, 2 the field of lipid study is turning more of its attention to the other lipoproteins that appear to be involved in atherosclerosis.The recent Adult Treatment Panel III (ATP III) report 1 of the National Cholesterol Education Program has summarized our current understanding of the relationship between other lipoprotein species and risk for coronary heart disease (CHD).

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000038419.53000.d6

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
National Cholesterol Education Program
Lenfant, C. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400060019005 · Cited by 1,188
Hypertriglyceridemia as a cardiovascular risk factor
Austin, M. A., Hokanson, J. E., & Edwards, K. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00031-9 · Cited by 1,066
National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
(1994) · Circulation · doi:10.1161/01.cir.89.3.1333 · Cited by 817
Epidemiology as a Guide to Clinical Decisions: The Association between Triglyceride and Coronary Heart Disease
Hulley, S. B., Rosenman, R. H., Bawol, R. D., & Brand, R. J. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006193022503 · Cited by 702
Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality
Cui, Y. A., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., LANGENBERG, P. W., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 657
Management of Dyslipidemia in NIDDM
Garg, A., & Grundy, S. M. (1990) · Diabetes Care · doi:10.2337/diacare.13.2.153 · Cited by 260
Self-citation
Fibrinogen and coronary heart disease--what does it mean?
Assmann, G., Schulte, H., Funke, H., & von Eckardstein, A. (1998) · PubMed · Cited by 256

Show all 25 references

Research works printed but not linked: 5

10.1161/circ.89.3.8124825 · DOI
10.1161/atvb.19.10.2474 · DOI
10.1161/circ.94.10.2381 · DOI
10.1161/circ.79.1.2642759 · DOI
1998, Eur Heart J, 19, M8

Sorted by citations

Items 201–300 of 308

Cholesterol and Triglyceride Management
Braun, L. T. (2010) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0b013e3181cec6d1 · Cited by 7
Treatment of hypertriglyceridemia
Capell, W. H., & Eckel, R. H. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0040-9 · Cited by 7
Non-HDL Cholesterol and Type 2 Diabetes Mellitus
Zabeen, S., Rahman, M., Mustafa, T., Eusufzai, N., & Shermin, S. (2012) · Anwer Khan Modern Medical College Journal · doi:10.3329/akmmcj.v3i2.11688 · Cited by 6
Cardiovascular Risk Among Patients with Controlled and Uncontrolled Type 2 Diabetes: A Sub-Cohort Analysis from the Heart Health Promotion (HHP) Study
Fayed, A. A., Alzeidan, R. A., Elkouny, R., Tawfik, M., & Naguib, R. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s404054 · Cited by 6
Analysis of the Correlation between Non-high Density Lipoprotein Cholesterol and Coronary Heart Disease in Elderly Chinese
Ke, D., Chen, Q., Wu, Q. F., Li, X., Wu, Z., Li, G., Deng, W., & Mo, X. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4988 · Cited by 6
Serum Lipid Profile Constituents as Markers of Cardiovascular Morbidity in Patients on Chronic Hemodialysis
Kirmizis, D. A., Koutoupa, E., Tsiandoulas, A., Valtopoulou, A., Niavis, G., Markou, P., & Barboutis, K. (2006) · Biomarker Insights · doi:10.1177/117727190600100010 · Cited by 6
Non-HDL as a Valid Surrogate Marker of Small Dense LDL in a Young Indian Population
Manocha, A., Bhargava, S., Jain, R., Kankra, M., Singla, P., & Chugh, P. (2018) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-018-0758-6 · Cited by 6
Niveles plasmáticos de apolipoproteínas en una población saludable de la Argentina: implicaciones en prevención cardiovascular
Siniawski, D. A., Masson, W. M., Bluro, I. M., Sorroche, P. B., Scordo, W., Krauss, J. G., & Cagide, A. M. (2025) · Revista Argentina de Cardiología · doi:10.7775/rac.v77i2.2158 · Cited by 6
Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULiPS (Turkish Lipid Study)
Ilerigelen, B., Üresin, Y., ŞAN, M. K., Kültürsay, H., Güneri, S., Serdar, O. A., Güleç, S., Pençedemir, H., & on behalf of the TULIPS investigators (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x187847 · Cited by 6
Changing lipid-lowering guidelines: whom to treat and how low to go
Ballantyne, C. M. (2005) · European Heart Journal Supplements · doi:10.1093/eurheartj/sui003 · Cited by 6
High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events
Fonarow, G. C., & Watson, K. E. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.01.014 · Cited by 6
Advances in Lipid Testing and Management in Patients with Diabetes Mellitus
Vasudevan, M. M., & Ballantyne, C. M. (2009) · Endocrine Practice · doi:10.4158/ep09190.ra · Cited by 5
Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy
Brown, W. V., Foody, J. M., Zieve, F. J., Tomassini, J. E., Shah, A. K., & Tershakovec, A. M. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.002 · Cited by 5
Genetic and Environmental Biomarkers Associated with Triglyceride Levels in Two Groups of Slovak Women
Daňková, Z., Vorobeľová, L., Čerňanová, V. C., Falbová, D., Grendár, M., Baldovič, M., Cvíčelová, M., & Siváková, D. (2016) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2016.0205 · Cited by 5
Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States
Maki, K. C., Benes, L. B., & Dicklin, M. R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_16 · Cited by 6
Type 1 Diabetes Mellitus
Beyan, H., & Leslie, R. D. G. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-517-6_12 · Cited by 5
How do conventional markers of lipid disorders compare with apolipoproteins?
Estonius, M., & Kallner, A. (2005) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510510013497 · Cited by 5
Are Measurements of LDL Particles Ready for Prime Time?
Stein, E. A. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.073452 · Cited by 5
Estimating LDL ApoB: Infomania or Clinical Advance?
Burnett, J. R., & Watts, G. F. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.104505 · Cited by 5
Re-Evaluating Therapeutic Target Goals for Statin-Treated Patients
Henkin, Y. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.018 · Cited by 5
The correlation of apolipoprotein B, apolipoprotein B/apolipoprotein A-I ratio and lipoprotein(a) with myocardial infarction
Agoşton-Coldea, L., Mocan, T., Gatfossé, M., & Dumitrascu, D. L. (2008) · Open Medicine · doi:10.2478/s11536-008-0057-3 · Cited by 4
Cardiometabolic and Metabolic Profiles of Lean/Normal, Overweight and Obese Patients with Nonalcoholic Fatty Liver Disease
Wang, S., Zhang, Y., Qi, X., & Xu, X. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s462003 · Cited by 4
The MERCURY II trial: benefits of rosuvastatin
Izzat, L. (2006) · The British Journal of Diabetes · doi:10.1177/14746514060060040501 · Cited by 4
Apo B/Apo A-I Ratio A Better Predictor of Coronary Artery Disease in Patients with or Without Type II Diabetes Mellitus.
Philip, S., Abraham, P., & Sheriff, D. S. (2014) · Cited by 4
Obesity and cardiovascular disease: expected and unexpected relationship
Pedone, C., Urbinati, S., Pallotti, M. G., & Pinelli, G. (2005) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2005.610 · Cited by 4
Type 1 Diabetes Mellitus
Gardner, D. W., Khan, K., Govindarajan, G., Palmer, J. C., & Sowers, J. R. (2006) · CRC Press eBooks · doi:10.3109/9781420019667-6 · Cited by 4
Therapie der Dyslipidämie bei entzündlich-rheumatischen Erkrankungen
Vordenbäumen, S., Schinner, S., Halle, M., Fischer‐Betz, R., & Schneider, M. (2010) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-009-0586-4 · Cited by 3
Bioactive Moringa olifera seed extracts attenuates cholesterol gall stones in hyperglycaemic Swiss mice
Salami, A. T., Okonkwo, C. E., Attah, A. F., & Olagoke, O. C. (2021) · Comparative Clinical Pathology · doi:10.1007/s00580-021-03206-3 · Cited by 3
Small Intestinal Bacterial Overgrowth in Patients with Gallbladder Polyps: A Cross-Sectional Study
Dong, C., Xian, R., Wang, G., & Cui, L. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s399812 · Cited by 3
The role of mipomersen therapy in the treatment of familial hypercholesterolemia
Plakogiannis, R., Cioce, L., Fisher, E. A. A., & Underberg, J. A. (2012) · Clinical Investigation · doi:10.4155/cli.12.96 · Cited by 3
Attitudes toward Hormone Replacement Therapy in the New Millennium: University Physicians’ and Patients’ Perspectives
Ismail, H. M., Aleveritis, E., Guha, B., Olive, K. E., & Sloan, S. M. (2005) · Journal of Investigative Medicine · doi:10.2310/6650.2005.53606 · Cited by 3
Lipid-Modifying and Antiatherosclerotic Drugs
Gotto, A. M., & Opie, L. H. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-6158-8.50015-0 · Cited by 3
Among young Sri Lankan patients with diabetes, how do lipid profiles differ between those with and without metabolic syndrome?
Katulanda, G. W., Dissanayake, H. A., Katulanda, P., Matthews, D. R., & Shine, B. S. F. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.07.002 · Cited by 3
Nuclear magnetic resonance technology and clinical applications
Franke, D. D. H., & Connelly, M. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815499-1.00011-9 · Cited by 3
Low-Density Lipoprotein, Non–High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
Feeman, W. E. (2003) · Circulation · doi:10.1161/01.cir.0000074259.01696.c6 · Cited by 3
Comparative evaluation of carvedilol and pitavastatin for antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats
Akbar, M., Ali, H., & Rahman, M. A. (2023) · Intelligent Pharmacy · doi:10.1016/j.ipha.2023.11.009 · Cited by 2
Linking elevated HbA1c with atherogenic lipid profile among high risk cardiovascular patients at Qassim, Saudi Arabia
Akasha, R., Ahmad, S., Abdeen, R., Abulgasim, S., Barnawi, H., Elhussein, N., Rehab Hussien, A., Alshammari, D., Elafandy, N. M., & Alouffi, S. (2024) · Bioinformation · doi:10.6026/973206300200212 · Cited by 2
Impact of Troponin Testing in Noncardiac Admissions
Tota-Maharaj, R., Perera, B. M., Murray, J., Petrini, J. R., & Keller, A. M. (2014) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000027 · Cited by 2
Avaliação do perfil lipídico entre indivíduos com hepatite C
Nogueira, C. T., Urbaczek, A. C., Falcoski, T. O. R., Isabel, T. F., Graminha, M. A. S., & da Costa, P. I. (2012) · Americanae (AECID Library) · Cited by 2
Optimal goals for statin use in patients with coronary artery disease
Ray, K. K., & Cannon, C. P. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000184529.52832.e6 · Cited by 2
Estudio de las repercusiones clínicas y analíticas de una intervención nutricional en pacientes no hospitalizados con claudicación intermitente. Estudio aleatorio controlado
Carrero, J. J., Salmerón-Febres, L. M., Ramos-Gutiérrez, V. E., López‐Huertas, E., & Ros-Die, E. (2006) · Angiología · doi:10.1016/s0003-3170(06)74946-x · Cited by 2
Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk Outcome
Al‐Rasadi, K., & Al-Sabti, H. A. (2015) · Oman Medical Journal · doi:10.5001/omj.2015.81 · Cited by 2
Overview of General Approach to Management of Elevated Low-Density Lipoprotein Cholesterol and Mixed Dyslipidemia, High Triglycerides, and Low High-Density Lipoprotein Cholesterol
Ballantyne, C. M., & Jones, P. H. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50021-4 · Cited by 2
Metabolic Syndrome
Sawhney, A. G., & Rothkopf, M. M. (2014) · CRC Press eBooks · doi:10.1201/b17616-7 · Cited by 2
Serum bilirubin levels are negatively associated with atherogenic lipids in Saudi subjects with type 2 diabetes: A pilot study
Alouffi, S. (2023) · Electronic Journal of General Medicine · doi:10.29333/ejgm/12777 · Cited by 2
Moderne Risikoanalyse bei intermediärem Risiko für kardiovaskuläre Ereignisse
Gohlke, H. (2007) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-007-0021-9 · Cited by 2
Obesity and metabolic syndrome: clinical and therapeutic review
Cuppini, A., & Matteini, P. (2005) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2005.612 · Cited by 2
Lípidos, aterogénesis y riesgo coronario
Evia, B., & Roberto, J. C. A. (2005) · Revista Latinoamericana de Patología Clínica y Medicina de Laboratorio · Cited by 2
Measurement of Atherogenic Lipoproteins in Cardiovascular Risk Assessment
Dunbar, R. L., & Rader, D. J. (2006) · Humana Press eBooks · doi:10.1007/978-1-59745-051-5_29 · Cited by 2
Pathophysiology and Management of Dyslipidemias Associated with Obesity, Type 2 Diabetes, and Other Insulin-Resistant States
Maki, K. C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_4 · Cited by 1
The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe
Akerström, F. O., & Padial, L. R. (2011) · Clinical Investigation · doi:10.4155/cli.10.14 · Cited by 1
Novel Lipids Targets in the Era of Metabolic Syndrome
Paneni, F., Palano, F., & Testa, M. (2009) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/11316980-000000000-00000 · Cited by 1
Laboratory Diagnostics of Dyslipidemia : From Cholesterol to Apolipoproteins
Leiviskä, J. (2013) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) · Cited by 1
New considerations in the design of clinical trials for anti-atherosclerotic drugs
Heinonen, T. M., & Black, D. M. (2011) · Clinical Investigation · doi:10.4155/cli.11.64 · Cited by 1
WITHDRAWN: Hypocholesterolemic Effects of diets supplemented with Kishk, as an Egyptian ethnic food
Ali, R. F. M. (2016) · Journal of Ethnic Foods · doi:10.1016/j.jef.2016.01.005 · Cited by 1
Raised Blood Cholesterol: Preventable Risk Factor for Cardiovascular Disease
Tokgözoğlu, L. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-22357-5_8 · Cited by 1
Cacao Polyphenols Influence the Regulation of Apolipoproteins
Osakabe, N. (2013) · Polyphenols in Human Health and Disease · doi:10.1016/b978-0-12-398456-2.00074-8 · Cited by 1
Special Patient Populations: Diabetes and Metabolic Syndrome
Kurra, S., Chahil, T. J., & Ginsberg, H. N. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50041-x · Cited by 1
Cardiovascular Disease in Racial and Ethnic Minorities
Ferdinand, K. C., & Armani, A. M. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.021 · Cited by 1
Special Patient Populations
Reyes‐Soffer, G., & Ginsberg, H. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00035-9 · Cited by 1
Pengaruh Terapi Suplementasi Fitosterol pada Profil Lemak Plasma, Kadar Apolipoprotein (Apo) B-48, dan Penghitungan Sel Busa Aorta Tikus Pascadiet Atherogenik
Triliana, R., Soeatmadji, D. W., & Kalim, H. (2014) · The Journal of Experimental Life Sciences · doi:10.21776/ub.jels.2012.002.02.03 · Cited by 1
Correlation between Non-High-Density Lipoprotein-Cholesterol and Hba1c Levels in Patients with Type 2 Diabetes Mellitus of Bengaluru City
Suguna, S., & Kusumadevi, M. S. (2019) · International Journal of Physiology · doi:10.37506/ijop.v7i3.132 · Cited by 1
Lipids, Atherogenic Dyslipidemia, and Therapy
Levine, T. B., & Levine, A. B. (2012) · Wiley eBooks · doi:10.1002/9781118480045.ch13 · Cited by 1
Avaliação nutricional de crianças a adolescentes portadores de imunodeficiências primárias e sua relação com os componentes da síndrome metabólica
Maneschy, I. R. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2015.tde-24082015-092045 · Cited by 1
Importancia del colesterol ligado a lipoproteínas de alta densidad (cHDL) en la prevención del riesgo cardiovascular. Recomendaciones del Foro HDL
Ascaso, J., Fernández‐Cruz, A., González Santos, P., Hernández Mijares, A., Mangas Rojas, A., Millán, J., Pallardo, L. F., Pedro‐Botet, J., Pérez‐Jiménez, F., Pía, G., et al. (2004) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(04)79003-8 · Cited by 1
Practice Patterns in Treating High-Risk Patients with Hyperlipidemia at a Northeast Tennessee University Clinic
Ismail, H. M., Simmons, C. A., & Pfortmiller, D. T. (2005) · Journal of Investigative Medicine · doi:10.2310/6650.2005.00003 · Cited by 1
The association of apolipoprotein B and low density lipoprotein with cardiovascular risk factors in the Thai population.
Krittayaphong, R., Chotinaiwattarakul, C., Kangkagate, C., Bhuripanyo, K., & Mahanonda, N. (2006) · PubMed · Cited by 1
Obesity and Atherosclerotic Vascular Disease
Jain, T., Plutzky, J., & McGuire, D. K. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420018905.016 · Cited by 1
DPP4 Polymorphisms Are Associated With Hypoalphalipoproteine mia and DPP4 Serum Levels. A Case-control Study of the GEA Cohort.Preprint
Vargas‐Alarcón, G., González-Salazar, M. D. C., Vázquez-Vázquez, C., Hernández-Díazcouder, A., Sánchez‐Muñoz, F., Reyes-Barrera, J., Críales-Vera, S., Sánchez-Guerra, M., Osorio-Yáñez, C., & Posadas‐Sánchez, R. (2020) · doi:10.21203/rs.3.rs-37788/v1 · Cited by 1
Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals
Reyes‐Soffer, G., & Ginsberg, H. N. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch17
Frecuencia de dislipidemia y estado nutricional de escolares de áreas rurales paraguayas
Sosa, L., Echagüe, G., Funes, P., Ramírez, A., Pistilli, N., Ruíz, I., Zenteno, J., Díaz, V., & Stanley, J. (2014) · DOAJ (DOAJ: Directory of Open Access Journals)
Monitoring of Lipids in Diabetes
Laker, M. F., & Neely, R. D. G. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0807
Non-high density lipoprotein-cholesterol and apolipoprotein B concentration in type 2 diabetes mellitus patients
Muenya, N., Deebukkhum, S., & Tangvarasittichai, S. (2013) · Warasan Theknik Kanphaet
Stężenie cholesterolu nie-HDL u nastolatków obciążonych klinicznymi czynnikami ryzyka miażdżycy
Obuchowicz, A. K., Kniażewska, M., Żmudzińska-Kitczak, J., & Jarecka, B. (2014) · Pediatria Polska · doi:10.1016/j.pepo.2014.07.005
Is there a future for CETP-inhibitor therapy?
Robinson, J. G. (2011) · Clinical Investigation · doi:10.4155/cli.11.10
¿Podemos utilizar la apolipoproteína B en la toma de decisiones para la intervención en el riesgo cardiovascular de pacientes con triglicéridos elevados?
Gerique, J. A. G., Gómez, B. A. L., Salán, M. E., Romero, F. F., Puzo, J., & Doreste, J. Á. A. (2012) · Revista del Laboratorio Clínico · doi:10.1016/j.labcli.2011.06.003
An update on the management of comorbid conditions in lupus nephritis
Tzavara, V., Pamfil, C. A. M., Boumpas, D. T., & Bertsias, G. K. (2013) · Clinical Investigation · doi:10.4155/cli.13.2
Alternate Approaches To Managing Lipid-Associated Cardiovascular Risk
Hsia, S. H. (2007) · Future Lipidology · doi:10.2217/17460875.2.2.157
INVESTIGATION OF THE REFERENCE VALUES OF THE ANKLE-BRACHIAL INDEX IN ASYMPTO- MATIC SEVERE HYPERCHOLESTEROLEMIA
Vladimirova‐Kitova, L. (2008)
Arterial hypertension in degenerative non-severe aortic stenosis
Jegier, B., Jaszewski, R., & Lelonek, M. (2011) · Open Medicine · doi:10.2478/s11536-011-0114-1
Association/National Heart, Lung, and Blood Institute Scientific Statement Diagnosis and Management of the Metabolic Syndrome: An American Heart
Smith, C. S., Spertus, J. A., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Grundy, S. M., Cleeman, J. I., Daniels, S. R., & Donato, K. A. (2006)
Self-citation
Hyper- and Dyslipoproteinemias
Kostner, K., & Kostner, G. M. (2013) · Springer eBooks · doi:10.1007/978-3-319-01050-2_3
Longer-term effects of early cholesterol intake on cholesterol biosynthesis and plasma lipids
Demmers, T. (2004) · doi:10.82308/49492
Role of statin therapy in the management of patients with the metabolic syndrome
Dembowski, E., & Davidson, M. H. (2007) · Archives of Medical Science
Niveles séricos de Apolipoproteínas A-I y B en niños escolares de escuelas rurales Serum Levels of Apolipoprotein A-I and B in Rural Schoolchildren
Jenny, L., Zenteno, J., Díaz, V., Ruíz, I., & Zárate, J. (2011)
NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL VERSUS APOLIPOPROTEIN B AS PREDICTORS FOR CORONARY HEART DISEASE
Aggarwal, J., Reddy, S., & Nagtilak, S. (2014) · International Journal of Pharma and Bio Sciences
The Metabolic Syndrome: Identification and Management of the Patient at High Risk for Cardiovascular Disease
Reasner, C. A. (2013) · CRC Press eBooks · doi:10.3109/9781420019667-17
Frecuencia de dislipidemia y estado nutricional de escolares de áreas rurales paraguayas Frequency of dislipidemia and nutritional state in schoolchildren of Paraguayan rural areas
Sosa, L., Echagüe, G., Funes, P., Ramírez, A., Pistilli, N., Zenteno, J., Díaz, & Stanley, J. (2014)
Management of Elevated Low-Density Lipoprotein Cholesterol
Davidson, M. H., & Robinson, J. G. (2013) · CRC Press eBooks · doi:10.3109/9781420019667-13
Women and Coronary Heart Disease
Bittner, V. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.020
Fibers and Prevention of Cardiovascular Disease
Noto, A. S., Zahradka, P. C., Marshall, T., & Taylor, C. (2012) · CRC Press eBooks · doi:10.1201/b11562-11
Novel therapeutic approaches to prevention and regression of atherosclerosis
Chyu, K., & Shah, P. K. (2012) · CRC Press eBooks · doi:10.3109/9781841848549.037
UNIVERSIDAD NACIONAL DE CÓRDOBA FACULTAD DE CIENCIAS MÉDICAS Estudio del Síndrome Metabólico en la población de Bulnes. Consideración de nuevos aspectos.
Bordese, F. J., & Argentina, R. (2012)
A Biochemical Study Of High-Density Lipoprotein Cholesterol (Hdl-C) Changes In Middle Aged Common People With Different Lifestyle
Kanna, K. S., Thamizhvanan, P., & Bharathi, J. (2017) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v16i2.25061
DESENVOLVIMENTO E VALIDAÇÃO DE METODOLOGIAS PARAAVALIAÇÃO DE EZETIMIBA POR CROMATOGRAFIA LÍQUIDA EESPECTROMETRIA DE MASSAS
de Oliveira, P. R. (2007) · Americanae (AECID Library)
A Study on the Prevalence and Impact of Metabolic Syndrome on Hospital Outcomes in Acute Myocardial Infarction
Arun, R. (2006)
Evaluation of the Analytical Performance of Atellica CH 930 Automated Chemistry Analyzer
Kim, D., Cho, Y., Cho, J., Kim, S. H., Lee, S., & Kim, J. (2019) · Laboratory Medicine Online · doi:10.3343/lmo.2019.9.3.133
How ApoB Measurements Could Improve Prevention of Cardiovascular Disease
Sniderman, A. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_29
Diabetes Mellitus
(2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-84628-135-0_3
Management of Elevated Low-Density Lipoprotein Cholesterol
Davidson, M. H., & Robinson, J. G. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.007

Authors: Grundy, S. M.
Affiliations: The University of Texas Southwestern Medical Center (US)
Corresponding author: Grundy, Scott M.
ORCID: Grundy, Scott M.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2002-11-12
Volume: 106
Issue: 20
Pages: 2526-2529
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.0000038419.53000.d6
OpenAlex: W2135020991
Cited by: 309
References: 25
Citations by year: 2025: 2 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 8 · 2020: 5 · 2019: 9 · 2018: 4 · 2017: 7 · 2016: 6 · 2015: 14 · 2014: 20 · 2013: 22 · 2012: 20
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: low-density lipoprotein, non-HDL cholesterol, apolipoprotein B, lipid-lowering therapy, VLDL, intermediate density lipoprotein, high-density lipoprotein, triglyceride-rich lipoproteins, atherogenesis, coronary heart disease risk, stroke risk, Adult Treatment Panel III
MeSH terms: Hypolipidemic Agents, Apolipoproteins B, Cholesterol, Coronary Artery Disease, Coronary Disease, Humans, Lipoproteins, Cholesterol, HDL, Lipoproteins, LDL, Prognosis, Risk Factors, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks